These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. Brynda J; Rezácová P; Fábry M; Horejsí M; Stouracová R; Soucek M; Hradílek M; Konvalinka J; Sedlácek J Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):1943-8. PubMed ID: 15502300 [TBL] [Abstract][Full Text] [Related]
4. A distinct binding mode of a hydroxyethylamine isostere inhibitor of HIV-1 protease. Dohnálek J; Hasek J; Dusková J; Petroková H; Hradilek M; Soucek M; Konvalinka J; Brynda J; Sedlácek J; Fábry M Acta Crystallogr D Biol Crystallogr; 2001 Mar; 57(Pt 3):472-6. PubMed ID: 11223536 [TBL] [Abstract][Full Text] [Related]
5. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478 [TBL] [Abstract][Full Text] [Related]
6. Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors. Johnson EC; Malito E; Shen Y; Pentelute B; Rich D; Florián J; Tang WJ; Kent SB J Mol Biol; 2007 Oct; 373(3):573-86. PubMed ID: 17869270 [TBL] [Abstract][Full Text] [Related]
7. Peptidomimetic inhibitors complexed with HIV-1 protease: crystallisation for X-ray diffraction studies. Dohnálek J; Hasek J; Brynda J; Fábry M; Sedlácek J; Konvalinka J; Hradilek M; Soucek M; Adams MJ; Naylor CE Gen Physiol Biophys; 1998 Jun; 17 Suppl 1():9-11. PubMed ID: 9789742 [No Abstract] [Full Text] [Related]
8. X-ray structure of HIV-1 protease tethered dimer complexed to ritonavir. Das A; Rao DR; Hosur MV Protein Pept Lett; 2007; 14(6):565-8. PubMed ID: 17627597 [TBL] [Abstract][Full Text] [Related]
9. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme. Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826 [TBL] [Abstract][Full Text] [Related]
10. Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor. Bhat TN; Baldwin ET; Liu B; Cheng YS; Erickson JW Nat Struct Biol; 1994 Aug; 1(8):552-6. PubMed ID: 7664084 [TBL] [Abstract][Full Text] [Related]
11. X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease. Jhoti H; Singh OM; Weir MP; Cooke R; Murray-Rust P; Wonacott A Biochemistry; 1994 Jul; 33(28):8417-27. PubMed ID: 8031777 [TBL] [Abstract][Full Text] [Related]
12. Crystallization and preliminary neutron diffraction studies of HIV-1 protease cocrystallized with inhibitor KNI-272. Matsumura H; Adachi M; Sugiyama S; Okada S; Yamakami M; Tamada T; Hidaka K; Hayashi Y; Kimura T; Kiso Y; Kitatani T; Maki S; Yoshikawa HY; Adachi H; Takano K; Murakami S; Inoue T; Kuroki R; Mori Y Acta Crystallogr Sect F Struct Biol Cryst Commun; 2008 Nov; 64(Pt 11):1003-6. PubMed ID: 18997326 [TBL] [Abstract][Full Text] [Related]
13. Structural studies of HIV-1 protease-inhibiting antibodies. Lescar J; Stouracova R; Riottot MM; Chitarra V; Brynda J; Fabry M; Horejsi M; Sedlacek J; Bentley GA Gen Physiol Biophys; 1998 Jun; 17 Suppl 1():3-6. PubMed ID: 9789740 [No Abstract] [Full Text] [Related]
14. A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor. Hoog SS; Zhao B; Winborne E; Fisher S; Green DW; DesJarlais RL; Newlander KA; Callahan JF; Moore ML; Huffman WF J Med Chem; 1995 Aug; 38(17):3246-52. PubMed ID: 7650677 [TBL] [Abstract][Full Text] [Related]
15. Use of molecular dynamics and free energy perturbation calculations in anti-human immunodeficiency virus drug design. McCarrick MA; Kollman P Methods Enzymol; 1994; 241():370-84. PubMed ID: 7854189 [No Abstract] [Full Text] [Related]
16. Crystal structure of chemically synthesized HIV-1 protease and a ketomethylene isostere inhibitor based on the p2/NC cleavage site. Torbeev VY; Mandal K; Terechko VA; Kent SB Bioorg Med Chem Lett; 2008 Aug; 18(16):4554-7. PubMed ID: 18657969 [TBL] [Abstract][Full Text] [Related]
17. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors. Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485 [TBL] [Abstract][Full Text] [Related]
18. Adaptability and flexibility of HIV-1 protease. Kumar M; Hosur MV Eur J Biochem; 2003 Mar; 270(6):1231-9. PubMed ID: 12631281 [TBL] [Abstract][Full Text] [Related]
19. Neutron crystallography used to identify targets to improve HIV-1 protease inhibitor. Hill R Future Med Chem; 2013 Oct; 5(15):1705. PubMed ID: 24144407 [No Abstract] [Full Text] [Related]
20. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Priestle JP; Fässler A; Rösel J; Tintelnot-Blomley M; Strop P; Grütter MG Structure; 1995 Apr; 3(4):381-9. PubMed ID: 7613867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]